DNA Therapeutics is a privately-owned biopharmaceutical company dedicated to the development of our original siDNA^® (signal interfering DNA) technology platform and medicine, which interfere with DNA damage repair pathways, to address unmet needs in treatment-resistant cancer.

Our lead molecule, Dbait, minics a DNA double strand break (DSB) to divert and disorganize the repair system responsible for recognizing and fixing DNA DSBs in cells. The aim of Dbait treatment is to compromise the ability of cancer cells to repair the DSBs inflicted by traditional cancer therapies, thus overcomes radio-/chemo-resistance and greatly improves therapeutic outcome.

The proofs of concept of Dbait was achieved in several human tumors xenografted onto nude mice by local or systemic administration in association with radiotherapy, and in spontaneous intestinal tumors in genetically engineered mice by systemic administration in associated with chemotherapy. Biomarkers of Dbait's bioactivity have been identified and are under development.

Dbait will be first administered locally, then systemically. This approach is in line with our clinical development strategy focused at first making clear-cut demonstration of the efficacy of Dbait in the indications where the current standard of care treatment fails to control tumor progression, then extending to other major segments of oncology market.

Dbait opens the era of supra-molecular therapy (multi-protein complex pathway targeting).

=> For more details, please check our flyer or fact sheet